reports
Soleno Therapeutics Announces Pricing of Approximately $138 Million Pu...
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share. The gross proceeds of the public offering are expected to be approximately $138.0 million, before deducting ...
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
Soleno Therapeutics Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares o...
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Compar...
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome Statistically Significant Improvements with DCCR Compared to Natural History of PWS from the PATH for PWS Study in Hyperphagia and PWS-related Behaviors REDWOOD CITY, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the comparison of results from the Company’s Phase ...
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S...
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 REDWOOD CITY, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing R...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 96,500 shares of common stock to six employees as an ind...
Comfort Systems Usa Inc: 1 director
A director at Comfort Systems Usa Inc sold 3,000 shares at 299.959USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing R...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to five new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 144,300 shares of common stock to five employees as an ...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quart...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2023. Full Year 2023 and Recent Corporate Highlights Announced positive statistically significant top-line data from the randomized withdrawal ...
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care...
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024, at 1:30 PM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s...
Soleno Therapeutics to Present at Upcoming February Investor Conferenc...
Soleno Therapeutics to Present at Upcoming February Investor Conferences REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the following upcoming investor conferences: Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceThursday, February 8, 2024, at 2:30 PM Eastern Time 34th Annual Oppenheimer Healthcare Life Sciences Co...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing R...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to five new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 246,000 shares of common stock to five employees as an i...
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
Soleno Therapeutics Strengthens Leadership Team with Key Appointments REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of th...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing R...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to three new employees. The independent members of the Board of Directors of Soleno, approved the grant of non-qualified stock options to purchase 102,500 shares of common stock to three employees, a...
Soleno Therapeutics Inc: 2 directors
Two Directors at Soleno Therapeutics Inc sold/sold after exercising options 44,073 shares at between 36.955USD and 38.292USD. The significance rating of the trade was 97/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...
Cadence Bank: 1 director
A director at Cadence Bank sold 45,000 shares at 27.130USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing R...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to two new employees. The Compensation Committee, consisting of independent members of the Board of Directors of Soleno, approved the grant of non-qualified stock options to purchase 145,000 shares of ...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarte...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 and Recent Corporate Highlights Announced positive statistically significant top-line data from the randomized withdrawal period of Study C602, a ...
Soleno Therapeutics Announces Peer-Reviewed Publication of Results fro...
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome One-Year Administration of DCCR in PWS Patients from DESTINY-PWS Demonstrates Significant Improvements in Hyperphagia and Other Behavioral Complications REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced publication of one-year results from the Phase 3 DESTINY PWS study and the...
- MarketLine Department
- Jonathan Moreland
OXBR OXBRIDGE RE HOLDINGS
MPAA MOTORCAR PARTS OF AMERICA INC.
MEI METHODE ELECTRONICS INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
DG DOLLAR GENERAL CORPORATION
CTRN CITI TRENDS INC.
COTY COTY INC. CLASS A
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
ADC AGREE REALTY CORPORATION
CCL CARNIVAL CORPORATION
POH3 CARNIVAL PLC
PAGP PLAINS GP HOLDINGS LP CLASS A
AGX ARGAN INC.
CSBR CHAMPIONS ONCOLOGY
ASTI ASCENT SOLAR TECHNOLOGIES
SLNO INC.
MHI SOLENO THERAPEUTICS INC
CDMO PIONEER MUNICIPAL HIGH INCOME TRUST
NKE AVID BIOSERVICES
BWB NIKE INC. CLASS B
VCNX BRIDGEWATER BANCSHARES
DOCU VACCINEX
CAPR DOCUSIGN INC.
IMVT CAPRICOR THERAPEUTICS
HQH IMMUNOVANT INC
HPK H&Q HEALTHCARE INVESTORS
AVO HIGHPEAK ENERGY INC (A)
PUBM MISSION PRODUCE
PRCH PUBMATIC
IMNM PORCH GROUP INC (A)
NRGX IMMUNOME
GNSS PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
RBLX GENASYS INC
ME ROBLOX
TKNO 23ANDME HOLDING CO.
ERAS ALPHA TEKNOVA
MPA INC.
GAIA ERASCA INC
BHVN BLACKROCK MUNIYIELD PENNSYLVANIA FD
BANX GAIA GROW CORP
MEIP AGILITI INC.
TTOO BIOHAVEN LTD
STONECASTLE FINANCIAL CORP.
MEI PHARMA INC.
T2 BIOSYSTEMS INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.